Neuroprotective effects of alisol A 24-acetate on cerebral ischaemia–reperfusion injury are mediated by regulating the PI3K/AKT pathway

Taotao Lu, Huihong Li, Yangjie Zhou, Wei Wei, Linlin Ding, Zengtu Zhan, Weilin Liu, Jing Tao, Xiehua XueJournal of Neuroinflammation 2022 · DOI

This study, published in the Journal of Neuroinflammation, investigates how Alisol A 24-acetate (24A)—a natural compound derived from the medicinal plant Alisma orientale—protects the brain following a stroke-like event. By using a mouse model of global cerebral ischemia-reperfusion (GCI/R), the researchers demonstrated that 24A significantly reduces brain inflammation and cell death by activating the PI3K/AKT signaling pathway, ultimately preserving cognitive function and neuronal structure.

TL;DR

Researchers have identified that Alisol A 24-acetate (24A) acts as a potent neuroprotective agent against ischemia-reperfusion injury. It works by "flipping the switch" on the PI3K/AKT pathway, which suppresses the inflammatory storm and apoptotic cell death that typically follow the restoration of blood flow to the brain.

What Problem Does This Paper Address?

Ischemic stroke occurs when blood flow to the brain is blocked. While restoring blood flow (reperfusion) is critical for survival, it paradoxically triggers a second wave of damage known as ischemia–reperfusion (I/R) injury. This phase is characterized by a massive release of inflammatory cytokines, oxidative stress, and programmed cell death (apoptosis).

Despite decades of research, effective neuroprotective drugs that can be administered post-stroke to limit this secondary damage are scarce. The authors focused on 24A because it is a known bioactive triterpenoid with anti-inflammatory properties, but its specific efficacy and mechanism of action in the context of global brain injury remained a "black box."

Methods

The study utilized a C57BL/6J mouse model of global cerebral ischemia, induced via the two-vessel occlusion (2-VO) method (temporarily clamping the common carotid arteries for 20 minutes).

The experimental design was robust, comparing four groups:

  1. Sham: Surgery without occlusion.
  2. GCI/R: Occlusion followed by saline.
  3. GCI/R + 24A: Occlusion followed by 30 mg/kg of 24A daily.
  4. GCI/R + 24A + LY294002: A "rescue" group where a PI3K inhibitor (LY) was added to see if it blocked 24A’s benefits.

Key techniques included: * Behavioral Testing: Morris water maze (spatial memory) and Novel Object Recognition (long-term memory). * Advanced Imaging: 3D Time-of-Flight MRA to confirm occlusion and Magnetic Resonance Spectroscopy (MRS) to measure real-time changes in brain metabolites like N-acetylaspartate (NAA) and Glutamate (Glx). * Histology: Golgi staining to visualize the microscopic "spines" on neurons and immunohistochemistry to track the activation of microglia and astrocytes (the brain's immune cells). * Molecular Biology: Western blotting to quantify proteins in the PI3K/AKT pathway and markers of inflammation/apoptosis.

Datasets

As this is a primary biological study rather than a computational one, the "dataset" consists of experimental results from cohorts of mice ($n=12$ per group for behavior, $n=3-6$ for molecular assays). No external large-scale genomic or proteomic datasets were used.

Key Insights and Ideas

  • Metabolic Fingerprinting: Using MRS, the authors found that 24A restored levels of NAA (a marker of neuronal health) and GABA, while lowering Glx (a marker of excitotoxicity). This suggests 24A helps stabilize the brain's chemical environment.
  • Structural Preservation: Beyond just keeping neurons alive, 24A preserved dendritic spines—the tiny protrusions where neurons connect. Loss of these spines is a hallmark of cognitive decline after stroke.
  • The PI3K/AKT "Master Switch": The most critical insight was that 24A’s benefits were almost entirely dependent on the PI3K/AKT pathway. When the researchers inhibited this pathway with the drug LY294002, the neuroprotective effects of 24A vanished, proving that this pathway is the primary mediator of the drug's action.
  • Glial Regulation: 24A didn't just target neurons; it significantly calmed overactive microglia and astrocytes, which are the primary drivers of neuroinflammation.

Key Results

  • Improved Behavior: 24A-treated mice showed significantly lower neurological deficit scores and performed better in the Morris water maze (more time spent in the target quadrant, $p < 0.05$).
  • Reduced Inflammation: Treatment led to a marked decrease in pro-inflammatory markers: IL-1β, TNF-α, and iNOS.
  • Anti-Apoptotic Effect: 24A shifted the balance of cell-death proteins, decreasing the Bax/Bcl-2 ratio and lowering levels of cleaved Caspase-3 (the "executioner" protein of cell death).
  • Pathway Activation: Western blots confirmed a significant increase in the phosphorylation (activation) of PI3K and AKT in the 24A group compared to the untreated GCI/R group ($p < 0.01$).

Limitations and Future Work

While promising, the study has a few notable limitations:

  1. Model Specificity: The 2-VO model simulates global ischemia (like cardiac arrest), which differs from focal ischemia (the most common type of human stroke).
  2. Timing: The study administered 24A starting 24 hours after reperfusion. Future studies should explore the "therapeutic window"—how late can the drug be given and still work?
  3. Bioavailability: As a triterpenoid, the metabolic stability and blood-brain barrier permeability of 24A in humans need further investigation before clinical trials.

The authors suggest that 24A represents a "promising and effective drug candidate" for treating ischemic brain diseases, providing a clear molecular target for future drug development.

Summary updated

Abstract

Taken together, our study indicated that 24A alleviated GCI/R injury by inhibiting neuroinflammation and apoptosis through the regulation of the PI3K/AKT pathway.
BibTeX
@article{lu2022neuroprotective,
  author = {Taotao Lu and Huihong Li and Yangjie Zhou and Wei Wei and Linlin Ding and Zengtu Zhan and Weilin Liu and Jing Tao and Xiehua Xue},
  title = {{Neuroprotective effects of alisol A 24-acetate on cerebral ischaemia–reperfusion injury are mediated by regulating the PI3K/AKT pathway}},
  journal = {Journal of Neuroinflammation},
  year = {2022},
  doi = {10.1186/s12974-022-02392-3},
}
Figure